Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Summary

Most of the lung cancer patients treated in hospitals in China are in advanced stage, accounting for more than 2/3 of all lung cancer patients, and some of the patients have a poor performence status.At present, most of the patients included in clinical trials are patients with good PS score, and the NCCN guidelines for advanced lung cancer patients with poor performence status recommend the best supportive care.Therefore, the investigator wanted to explore the efficacy and safety of Almonertinib in lung cancer patients with poor performance status.

Timeline

Start

2022-01-01

Primary completion

2024-12-28

Completion

2024-12-30

Drugs

Indications